首页 > R&D Systems > R&D Systems/Human Nogo-A aa 566-748 Antibody/AF3515-SP/25 ug

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

R&D Systems/Human Nogo-A aa 566-748 Antibody/AF3515-SP/25 ug

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

AF3515-SP-25ug

品牌：

R&D Systems

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Species ReactivityHumanSpecificityDetects human Nogo-A in direct ELISAs and Western blots. In direct ELISAs, approximately 5% cross-reactivity with recombinant rat Nogo-A (aa 543-725) and recombinant human Nogo-B is observed..SourcePolyclonal Sheep IgGPurificationAntigen Affinity-purifiedImmunogenChinese hamster ovary cell line CHO-derived recombinant human Nogo-A Val566-Phe748Accession # Q9NQC3FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.LabelUnconjugated Western Blot0.1 µg/mLRecombinant Human Nogo-A Fc Chimera, aa 566-748 (Catalog # 3515-NG)Immunocytochemistry5-15 µg/mLSee belowReconstitutionReconstitute at 0.2 mg/mL in sterile PBS.ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °CStability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.6 months, -20 to -70 °C under sterile conditions after reconstitution. References:Oertle, T. et al. (2003) FASEB J. 17:1238.GrandPre, T. et al. (2000) Nature 403:439.Yan, R. et al. (2006) Cell. Mol. Life Sci. 63:877.Teng, F.Y.H. et al. (2004) J. Neurochem. 89:801.Chen, M.S. et al. (2000) Nature 403:434.Morris, N.J. et al. (1999) Biochim. Biophys. Acta 1450:68.GenBank Accession # Q9NQC3.Oertle, T. et al. (2003) J. Neurosci. 23:5393.Fournier, A.E. et al. (2001) Nature 409:341.Wang, K.C. et al. (2002) Nature 420:74.Prinjha, R. et al. (2000) Nature 403:384.Dodd, D.A. et al. (2005) J. Biol. Chem. 280:12494.Li, M. et al. (2004) Eur. J. Biochem. 271:3512.Huber, A.B. and M.E. Schwab (2000) Biol. Chem. 381:407.Ng, C.E.L. and B.L. Tang (2002) J. Neurosci. Res. 67:559.Dodd, D.A. et al. (2005) J. Biol. Chem. 280:12494.Wang, X. et al. (2002) J. Neurosci. 22:5505.Acevedo, L. et al. (2004) Nat. Med. 10:382. Long Name:Reticulon 4AEntrez Gene IDs:57142 (Human); 68585 (Mouse); 83765 (Rat)Alternate Names:NI220; NogoA; Nogo-A; RTN4; RTN4ABackground:Human Nogo-A (also reticulon-4) is a member of the reticulon family of transmembrane proteins. This family is characterized by the presence of a nonsignal sequence-containing N-terminus, a topologically conserved 200 amino acid (aa) C-terminus that contains two transmembrane domains with an ER-retention motif, and a punctate intracellular distribution within the ER that is reminescent of a reticulum (1-4). In human, Nogo exists in five isoforms (5-7). The full length human form (Nogo-A) is 1192 aa in length and contains a 1018 aa N-terminus, a 21 aa transmembrane segment, a 94 aa connecting “loop”, a second 21 aa transmembrane segment, and a 38 aa C-terminus. Three areas are of particular interest. One is a stretch of 66 aa within the 94 aa connecting loop. This segment is reported to bind to the GPI-linked Nogo receptor/p75 complex on axons and induce growth cone collapse (8-10). Two other areas in the N-terminus have also been discovered to have bioactivity (8, 11, 12). Based on rat, aa 57-184 in human (aa 59-172 in rat) should block fibroblast spreading, while aa 566-748 in human (aa 544-725 in rat) block neurite outgrowth and block fibroblast spreading (8, 12, 13). The exact topology of Nogo-A is unclear. The N- and C-termini may be extracellular with the “loop” region intracellular, or the situation could be reversed (13-15). Alternatively, the loop region and N-terminus may be on the same side of the membrane (3, 8). The four additional isoforms are shorter than Nogo-A (199 aa [Nogo-C], 373 aa [Nogo-B], 392 aa and 986 aa, respectively) (7). Although highly divergent, all contain the same C-terminal stretch, aa 1005-1192. Both Nogo-B and C are reported to complex with Nogo-A (16). Notably, Nogo-A is expressed in neurons, endothelial cells. oligodendrocytes, fibroblasts and myoblasts (12, 16-18). Human Nogo-A is 78% aa identical to mouse and rat Nogo-A overall, with 98% aa identity in the loop region and approximately 80% aa identity in the aa 566-748 segment.

R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。